Related Experiment Video

Updated: Oct 1, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Intensive blood pressure reduction is beneficial in patients with impaired cardiac function coexisting with chronic

Naofumi Ikeda1, Hiromichi Suzuki, Kenshi Moriwaki

  • 1Department of Nephrology, Saitama Medical College, Saitama, Japan.

Hypertension Research : Official Journal of the Japanese Society of Hypertension
|April 2, 2002
PubMed

Insights

Intensive blood pressure reduction in patients with congestive heart failure (CHF) and chronic renal insufficiency (CRI) maintained cardiac and renal function better than standard reduction. This suggests intensive BP management benefits cardiorenal failure patients.

Area of Science:

  • Cardiology
  • Nephrology
  • Hypertension Management

Background:

  • Blood pressure reduction benefits cardiac and renal function in congestive heart failure (CHF) and chronic renal insufficiency (CRI).
  • Optimal blood pressure targets for patients with both CHF and CRI remain uncertain.

Purpose of the Study:

  • To investigate whether intensive blood pressure reduction is more beneficial than standard reduction in patients with coexisting CHF and CRI.
  • To compare the effects of two different blood pressure targets on cardiac and renal function over a 2-year period.

Main Methods:

  • A study involving 56 patients (35 men, 21 women, average age 63) with CHF (ejection fraction <55%) and CRI (GFR <50 ml/min).
  • Patients were divided into two groups: Group I targeted BP <120/75 mmHg, Group II targeted BP <130/80 mmHg.
  • Standard antihypertensive medications were used, with a 2-year follow-up to assess BP, ejection fraction (EF), and glomerular filtration rate (GFR).

Main Results:

  • Group I (intensive BP reduction) maintained EF (46±4% to 60±4%) and GFR (44±4 to 40±3 ml/min) with a final BP of 118±4/73±3 mmHg.
  • Group II (standard BP reduction) showed a reduction in EF (46±4% to 42±3%) and a significant decrease in GFR (44±3 to 35±3 ml/min) with a final BP of 128±4/81±2 mmHg.

Conclusions:

  • Intensive blood pressure reduction to below 120/75 mmHg may be beneficial for preserving cardiac and renal function in patients with cardiorenal failure.
  • These findings suggest a potential benefit of more aggressive BP management in this complex patient population.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various tubules...